Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review

Abdel-Rahman, Omar, Oweira, Hani, Petrausch, Ulf, Helbling, Daniel, Schmidt, Jan, Mannhart, Meinrad, Mehrabi, Arianeb, Schöb, Othmar, Giryes, Anwar · 2017 · Expert Review of Anticancer Therapy

Abstract

INTRODUCTION: Immune-related ocular toxicities are uncommon but serious adverse events that may be associated with the use of immune checkpoint inhibitors. The objective of this review is to assess the incidence and risk of ocular toxicities which are potentially immune-related and occur with immune checkpoint treatment of solid tumors. Areas covered: PubMed database has been searched till June 2016. Prospective clinical trials reporting the occurrence of immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors were included. Eleven trials with 4965 participants were included. These studies included one study for ipilimumab and tremelimumab, three studies for nivolumab, five studies for pembrolizumab and one study comparing pembrolizumab to ipilimumab. No atezolizumab studies were included. The most common ocular toxicities reported with these agents included uveitis and dry eyes. Pooled analysis for odds ratio of all-grade immune-related ocular toxicities is 3.40 [95% CI: 1.32-8.71; P = 0.01]. Expert commentary: Despite being uncommon, immune-related ocular toxicities (particularly uveitis and dry eyes) occur with a higher frequency in cancer patients treated immune checkpoint inhibitors compared to those treated with control regimens.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1080/14737140.2017.1296765

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 161

Metadata

Authors
Abdel-Rahman, O., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O., & Giryes, A.
Venue
Expert Review of Anticancer Therapy
Published
2017-02-24
Volume
17
Issue
4
Pages
387-394
ISSN
  • 1473-7140 (ISSN-L)
  • 1744-8328
OpenAlex
W2587959153
Cited by
161
References
23
FWCI
2.03
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. https://app.cochat.ai/papers/10.1080/14737140.2017.1296765
The paper
Abdel-Rahman, O., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O., & Giryes, A. (2017). Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Review of Anticancer Therapy. https://doi.org/10.1080/14737140.2017.1296765

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.